BUY, SELL, HOLD (2)

Analyst: This Drug Stock Could Surge 60%

RCKT shares have nearly doubled in 2018

Jul 10, 2018 at 2:13 PM
facebook X logo linkedin


The shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) -- which specializes in rare disease therapies -- are higher today, thanks to some bullish analyst attention. Specifically, William Blair initiated coverage of RCKT stock with an "outperform" rating and a fair-value target of $32 -- representing expected upside of 63% from the security's close of $19.68 on Monday. The analyst wrote that Rocket Pharma has "ambitious goals for a relatively young company, [but] execution on this strategy could unlock significant value creation for shareholders."

Rocket Pharmaceuticals stock was last seen 3.9% higher to trade at $20.45. The company merged with Inotek Pharmaceuticals in early January, and has nearly doubled year-to-date, with pullbacks contained by its 80-day moving average. Further, RCKT stock today is set to end atop its 20-day moving average for the first time since June 20, when the shares were still lingering near annual-high territory.

RCKT stock chart july 10

An unwinding of short interest could also propel RCKT higher. Short interest jumped 52.2% during the past two reporting periods, and now accounts for more than 2 million Rocket Pharmaceuticals shares. At the security's average pace of trading, it would take more than six sessions to repurchase these pessimistic positions -- ample fuel for a short squeeze.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.